GlaxoSmithKline has withdrawn its patent application for anti-AIDS drug --- Combivir. Earlier, GSK also has withdrawn Combivir patent application in Thailand after facing a strong opposition from thousands of AIDS patients. Back in India, the Combivir patent application was also facing strong opposition from NGOs who filed pre-grant opposition in the Kolkata Patent Office contending that the Combivir as such is not an invention rather a mere combination of existing drugs, namely, Zidovudine and Lamivudine. GSK sources, however, said the company’s move is in public interest and is part of its policy routine review of patent applications.
No comments:
Post a Comment